Recruitment

Recruitment Status
Completed

Exclusion Criterias

History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
Current or prior history of clinical hepatic decompensation (Groups 1 and 2 only)
Pregnant or nursing female or male with pregnant female partner
...
History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
Current or prior history of clinical hepatic decompensation (Groups 1 and 2 only)
Pregnant or nursing female or male with pregnant female partner
Co-infection with HIV or hepatitis B virus (HBV)
Hepatocellular carcinoma (HCC)

Summary

Conditions
HCV Infection
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Exclusion Criterias

History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
Current or prior history of clinical hepatic decompensation (Groups 1 and 2 only)
Pregnant or nursing female or male with pregnant female partner
...
History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
Current or prior history of clinical hepatic decompensation (Groups 1 and 2 only)
Pregnant or nursing female or male with pregnant female partner
Co-infection with HIV or hepatitis B virus (HBV)
Hepatocellular carcinoma (HCC)

Locations

Marietta, Georgia, 30060
Germantown, Tennessee, 38138
Albuquerque, New Mexico, 87131
Beverly Hills, California, 90210
Kansas City, Missouri, 64131
...
Marietta, Georgia, 30060
Germantown, Tennessee, 38138
Albuquerque, New Mexico, 87131
Beverly Hills, California, 90210
Kansas City, Missouri, 64131
Los Angeles, California, 90036
San Antonio, Texas, 78215
Indianapolis, Indiana, 46237
Wellington, Florida, 33414
San Diego, California, 92103
New York, New York, 10029
Baton Rouge, Louisiana, 70809
Richmond, Virginia, 23226
Los Angeles, California, 90027
Bowling Green, Kentucky, 42101
Hillsborough, New Jersey, 08844
Norfolk, Virginia, 23502
Baltimore, Maryland, 21229
San Francisco, California, 94115
Minneapolis, Minnesota, 55414
Manhasset, New York, 11030
Washington, District of Columbia, 20009
Downers Grove, Illinois, 60515
Asheville, North Carolina, 28801
La Jolla, California, 92037
Boston, Massachusetts, 02215
San Juan, 00927
Seattle, Washington, 98111
Winston-Salem, North Carolina, 27103
Los Angeles, California, 90069
Springfield, Massachusetts, 01105
Jacksonville, Florida, 32256
Camperdown, New South Wales, 2050
Binghamton, New York, 13903
Clichy, 92110
Orlando, Florida, 32803
Chicago, Illinois, 60611
Oceanside, California, 92056
Aurora, Colorado, 80045
Miami, Florida, 33136
Gainesville, Florida, 32610
Philadelphia, Pennsylvania, 19104
Barcelona, 08028

Tracking Information

NCT #
NCT01987453
Collaborators
Not Provided
Investigators
Study Director: Gilead Study Director Gilead Sciences